Showing 5211-5220 of 21466 results for "".
- Simultaneous Skin Pinch Blepharoplasty, Full-Field Er:YAG Resurfacing Shows Favorable Outcomes for Lower Eyelid Rejuvenationhttps://reachmd.com/news/simultaneous-skin-pinch-blepharoplasty-full-field-eryag-resurfacing-shows-favorable-outcomes-for-lower-eyelid-rejuvenation/2487318/A combined approach incorporating lower eyelid skin pinch blepharoplasty and full-field erbium:YAG laser resurfacing demonstrated favorable aesthetic outcomes with a low complication rate in a retrospective case series published online ahead of print in the Journal of Cosmetic and Laser Thera
- Anselamimab Misses Overall Endpoint, Signals Kappa Benefit In CAREShttps://reachmd.com/news/anselamimab-misses-overall-endpoint-signals-kappa-benefit-in-cares/2487306/Key Takeaways Anselamimab was not associated with a significant advantage on the primary hierarchical composite endpoint in the full randomized population. Among patients with kappa isotype, lower mortality, fewer cardiovascular hospitalizations, and b
- Semaglutide Meta-Analysis Finds Lower Mortality and Kidney Eventshttps://reachmd.com/news/semaglutide-meta-analysis-finds-lower-mortality-and-kidney-events/2487307/Key Takeaways Semaglutide was linked with lower mortality in the pooled analysis and with fewer major adverse cardiovascular events than placebo. Lower rates were also reported for nonfatal myocardial infarction, worsening heart failure, and kidney out
- Efgartigimod Shows Rapid Short-Term Responses in Juvenile MG Cohorthttps://reachmd.com/news/efgartigimod-juvenile-mg/2487299/Key Takeaways Improvement was observed by week 1 and continued through week 4 across the short observation window. Minimal symptom expression was reported in 66.7% (8/12) of evaluable patients by week 4. Patients remained on background immunos
- Aflibercept 8 mg Sustains 96-Week Outcomes in PULSAR nAMD Trialhttps://reachmd.com/news/aflibercept-8-mg-sustains-96-week-outcomes-in-pulsar-namd-trial/2487292/Key Takeaways Week 96 visual and anatomic outcomes were maintained, and BCVA differences versus 2q8 met the noninferiority criteria specified for the primary end point at week 48. Extended intervals were common with aflibercept 8 mg among patients comp
- Ruxolitinib Cream in Lichen Sclerosus: Phase 2 Trial Resultshttps://reachmd.com/news/ruxolitinib-cream-in-lichen-sclerosus-phase-2-trial-results/2487276/Key Takeaways Greater improvement in total Clinical Lichen Sclerosus Score was observed with ruxolitinib than with vehicle at week 12. The proportion reaching Itch NRS4 at week 12 was similar in the ruxolitinib and vehicle groups. Application-
- Melatonin Falls Short In Neuropathic Pain Crossover Trialhttps://reachmd.com/news/melatonin-falls-short-in-neuropathic-pain-crossover-trial/2487281/Key Takeaways Melatonin did not show a primary pain advantage over placebo in the crossover comparison. No secondary outcomes differed significantly, including measures of sleep, mood, and quality of life. Treatment-emergent adverse events wer
- Short-Term Tolerability of Blood Pressure-Lowering Drugs and Combinationshttps://reachmd.com/news/short-term-tolerability-of-blood-pressure-lowering-drugs-and-combinations/2487280/Key Takeaways Angiotensin II receptor blocker–containing regimens ranked among the best tolerated, with angiotensin II receptor blocker plus calcium channel blocker at the top. Higher discontinuation due to adverse events was observed with calcium chan
- ACL Reconstruction With LET in Athletes: Randomized Trial Findingshttps://reachmd.com/news/acl-reconstruction-with-let-in-athletes-randomized-trial-findings/2487289/Key Takeaways Adding modified Lemaire LET to ACL reconstruction was associated with better Lysholm, IKDC, and KT1000 side-to-side results at 12 months. Enrollment was limited to athlete patients younger than 40 years with isolated ACL tear, no meniscal
- Three-Year Real-World Outcomes With Dupilumab In Severe Asthmahttps://reachmd.com/news/three-year-real-world-outcomes-with-dupilumab-in-severe-asthma/2487282/Key Takeaways At 36 months, 59% of patients continued dupilumab and 41% had discontinued treatment. Among patients who remained on therapy for 36 months, exacerbations and oral corticosteroid use fell while asthma control and lung function improved.